vs
Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and SYPRIS SOLUTIONS INC (SYPR). Click either name above to swap in a different company.
GYRE THERAPEUTICS, INC. is the larger business by last-quarter revenue ($37.2M vs $30.3M, roughly 1.2× SYPRIS SOLUTIONS INC). GYRE THERAPEUTICS, INC. runs the higher net margin — -3.7% vs -12.9%, a 9.2% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs -9.5%). SYPRIS SOLUTIONS INC produced more free cash flow last quarter ($-1.5M vs $-5.8M). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs -7.7%).
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
Sypris Solutions Inc. is a U.S.-headquartered provider of highly engineered components and specialized technical services, primarily serving aerospace, defense, automotive and commercial industrial markets. It delivers custom manufacturing, performance testing, and value-added engineering support for mission-critical systems and parts for global enterprise clients.
GYRE vs SYPR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $37.2M | $30.3M |
| Net Profit | $-1.4M | $-3.9M |
| Gross Margin | 95.3% | 4.6% |
| Operating Margin | 0.3% | -10.9% |
| Net Margin | -3.7% | -12.9% |
| Revenue YoY | 33.4% | -9.5% |
| Net Profit YoY | -340.1% | -2992.6% |
| EPS (diluted) | $-0.01 | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $37.2M | $30.3M | ||
| Q3 25 | $30.6M | $28.7M | ||
| Q2 25 | $26.8M | $31.4M | ||
| Q1 25 | $22.1M | $29.5M | ||
| Q4 24 | $27.9M | $33.4M | ||
| Q3 24 | $25.5M | $35.7M | ||
| Q2 24 | $25.2M | $35.5M | ||
| Q1 24 | $27.2M | $35.6M |
| Q4 25 | $-1.4M | $-3.9M | ||
| Q3 25 | $5.9M | $517.0K | ||
| Q2 25 | $1.6M | $-2.1M | ||
| Q1 25 | $3.7M | $-899.0K | ||
| Q4 24 | $569.0K | $135.0K | ||
| Q3 24 | $2.9M | $390.0K | ||
| Q2 24 | $4.5M | $16.0K | ||
| Q1 24 | $9.9M | $-2.2M |
| Q4 25 | 95.3% | 4.6% | ||
| Q3 25 | 94.7% | 7.2% | ||
| Q2 25 | 95.7% | 8.2% | ||
| Q1 25 | 95.9% | 11.4% | ||
| Q4 24 | 95.8% | 16.1% | ||
| Q3 24 | 96.2% | 16.8% | ||
| Q2 24 | 96.9% | 15.9% | ||
| Q1 24 | 96.4% | 8.1% |
| Q4 25 | 0.3% | -10.9% | ||
| Q3 25 | 22.7% | -6.1% | ||
| Q2 25 | 8.1% | -4.6% | ||
| Q1 25 | 10.3% | -0.4% | ||
| Q4 24 | 2.4% | 3.9% | ||
| Q3 24 | 16.6% | 4.8% | ||
| Q2 24 | 12.7% | 3.6% | ||
| Q1 24 | 29.7% | -3.9% |
| Q4 25 | -3.7% | -12.9% | ||
| Q3 25 | 19.4% | 1.8% | ||
| Q2 25 | 5.9% | -6.5% | ||
| Q1 25 | 16.9% | -3.0% | ||
| Q4 24 | 2.0% | 0.4% | ||
| Q3 24 | 11.2% | 1.1% | ||
| Q2 24 | 18.0% | 0.0% | ||
| Q1 24 | 36.6% | -6.2% |
| Q4 25 | $-0.01 | $-0.17 | ||
| Q3 25 | $0.03 | $0.02 | ||
| Q2 25 | $0.00 | $-0.09 | ||
| Q1 25 | $0.00 | $-0.04 | ||
| Q4 24 | $0.00 | $0.00 | ||
| Q3 24 | $0.01 | $0.02 | ||
| Q2 24 | $0.01 | $0.00 | ||
| Q1 24 | $0.03 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $52.4M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $106.0M | $17.8M |
| Total Assets | $166.1M | $107.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $52.4M | — | ||
| Q3 25 | $60.0M | — | ||
| Q2 25 | $54.4M | — | ||
| Q1 25 | $29.9M | — | ||
| Q4 24 | $26.7M | — | ||
| Q3 24 | $25.1M | — | ||
| Q2 24 | $25.1M | — | ||
| Q1 24 | $37.4M | — |
| Q4 25 | $106.0M | $17.8M | ||
| Q3 25 | $101.9M | $20.0M | ||
| Q2 25 | $92.0M | $18.7M | ||
| Q1 25 | $68.1M | $19.0M | ||
| Q4 24 | $63.3M | $19.6M | ||
| Q3 24 | $63.2M | $18.2M | ||
| Q2 24 | $60.4M | $19.0M | ||
| Q1 24 | $56.6M | $20.8M |
| Q4 25 | $166.1M | $107.8M | ||
| Q3 25 | $159.4M | $112.5M | ||
| Q2 25 | $152.6M | $105.8M | ||
| Q1 25 | $129.8M | $110.2M | ||
| Q4 24 | $125.4M | $119.4M | ||
| Q3 24 | $125.2M | $121.6M | ||
| Q2 24 | $120.9M | $124.2M | ||
| Q1 24 | $122.0M | $129.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.6M | $-1.1M |
| Free Cash FlowOCF − Capex | $-5.8M | $-1.5M |
| FCF MarginFCF / Revenue | -15.5% | -5.0% |
| Capex IntensityCapex / Revenue | 0.4% | 1.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-180.0K | $-6.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.6M | $-1.1M | ||
| Q3 25 | $4.7M | $-178.0K | ||
| Q2 25 | $2.1M | $1.1M | ||
| Q1 25 | $-129.0K | $-5.5M | ||
| Q4 24 | $-2.8M | $2.3M | ||
| Q3 24 | $1.7M | $-4.8M | ||
| Q2 24 | $-5.5M | $6.2M | ||
| Q1 24 | $2.9M | $-1.7M |
| Q4 25 | $-5.8M | $-1.5M | ||
| Q3 25 | $4.0M | $-390.0K | ||
| Q2 25 | $1.8M | $941.0K | ||
| Q1 25 | $-251.0K | $-5.5M | ||
| Q4 24 | $-2.8M | $1.9M | ||
| Q3 24 | $1.0M | $-4.9M | ||
| Q2 24 | $-6.9M | $6.0M | ||
| Q1 24 | $2.7M | $-2.0M |
| Q4 25 | -15.5% | -5.0% | ||
| Q3 25 | 13.1% | -1.4% | ||
| Q2 25 | 6.8% | 3.0% | ||
| Q1 25 | -1.1% | -18.8% | ||
| Q4 24 | -10.1% | 5.7% | ||
| Q3 24 | 4.1% | -13.8% | ||
| Q2 24 | -27.5% | 16.8% | ||
| Q1 24 | 9.8% | -5.7% |
| Q4 25 | 0.4% | 1.3% | ||
| Q3 25 | 2.2% | 0.7% | ||
| Q2 25 | 1.0% | 0.5% | ||
| Q1 25 | 0.6% | 0.0% | ||
| Q4 24 | 0.2% | 1.2% | ||
| Q3 24 | 2.7% | 0.4% | ||
| Q2 24 | 5.8% | 0.5% | ||
| Q1 24 | 0.9% | 0.9% |
| Q4 25 | — | — | ||
| Q3 25 | 0.79× | -0.34× | ||
| Q2 25 | 1.32× | — | ||
| Q1 25 | -0.03× | — | ||
| Q4 24 | -4.85× | 17.13× | ||
| Q3 24 | 0.60× | -12.21× | ||
| Q2 24 | -1.21× | 385.25× | ||
| Q1 24 | 0.29× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GYRE
Segment breakdown not available.
SYPR
| Sypris Electronics | $17.7M | 59% |
| Transferred At Point In Time | $12.5M | 41% |
